Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

4/8/2025

Janusmed kön och genus

Janusmed kön och genus – Terbinafin Hexal

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Terbinafin – systemiskt Testmiljö

Terbinafin – systemiskt

Klass : A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Azurifin, Lamisil, Terbinafin 2care4, Terbinafin Arrow, Terbinafin Blu......

Azurifin, Lamisil, Terbinafin 2care4, Terbinafin Arrow, Terbinafin Bluefish, Terbinafin Ebb, Terbinafin Hexal, Terbinafin Medical Valley, Terbinafin Mylan, Terbinafin Orifarm, Terbinafin STADA, Terbinafin ratiopharm
ATC-koder

D01BA02

D01BA02
Substanser

terbinafin, terbinafinhydroklorid

terbinafin, terbinafinhydroklorid
Sammanfattning

Kvinnor och män har likvärdig effekt av terbinafin vid behandling av tånagelsvamp.

Kvinnor och män har likvärdig effekt av terbinafin vid behandling av tånagelsvamp.
Background

Most  published studies show a higher prevalence of onychomycosis in men. However, the male/female ratio varies between study population and study types. In population-based studies, the male/female ratio was 1.6. In hospital-based studies, the male/female ratio was 1.9 in North America, 1.5 in Europe, 0.8 in South America [1].

Pharmacokinetics and dosing
No studies with a sex analysis regarding the pharmacokinetics or dosing of terbinafine have been found.

Effects
No sex differences in patient-reported outcomes were shown after 12 weeks of treatment with oral terbinafine 250 mg/day in patients with toenail onychomycosis (309 men, 195 women) [2]. Also, another smaller study in patients with toenail onychomycosis treated with terbinafine 250 mg/day for 12 weeks (40 men, 34 women) showed no sex differences in mycological cure (defined as negative 20% KOH test and a negative mycological culture) [3].

Adverse effects
No studies with a sex analysis regarding adverse effects of terbinafine have been found.

Reproductive health issues
Regarding teratogenic aspects, please consult Jan......

Visa hela bakgrundstexten

Most  published studies show a higher prevalence of onychomycosis in men. However, the male/female ratio varies between study population and study types. In population-based studies, the male/female ratio was 1.6. In hospital-based studies, the male/female ratio was 1.9 in North America, 1.5 in Europe, 0.8 in South America [1]. # Pharmacokinetics and dosing No studies with a sex analysis regarding the pharmacokinetics or dosing of terbinafine have been found. # Effects No sex differences in patient-reported outcomes were shown after 12 weeks of treatment with oral terbinafine 250 mg/day in patients with toenail onychomycosis (309 men, 195 women) [2]. Also, another smaller study in patients with toenail onychomycosis treated with terbinafine 250 mg/day for 12 weeks (40 men, 34 women) showed no sex differences in mycological cure (defined as negative 20% KOH test and a negative mycological culture) [3]. # Adverse effects No studies with a sex analysis regarding adverse effects of terbinafine have been found. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler män än kvinnor hämtade ut tabletter innehållande terbinafin (ATC-kod D01BA02) på recept i Sverige år 2021, totalt 12 425 män och 7 380 kvinnor. Det motsvarar 2,4 respektive 1,4 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 45-54 år hos båda könen. I genomsnitt var tabletter innehållande terbinafin 1,7 gånger vanligare hos män [4].
Referenser

Visa referenser

  1. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014;28:1480-91.

  2. Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18(1):46-52.

  3. Cohen AD, Medvesovsky E, Shalev R, Biton A, Chetov T, Naimer S et al. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis. J Dermatolog Treat. 2003;14:237-42.

  4. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]

  1. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014;28:1480-91.
  2. Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18(1):46-52.
  3. Cohen AD, Medvesovsky E, Shalev R, Biton A, Chetov T, Naimer S et al. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis. J Dermatolog Treat. 2003;14:237-42.
  4. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]
Uppdaterat

Litteratursökningsdatum: 9/16/2022

Litteratursökningsdatum: 9/16/2022
Fasstexter

Visa fasstexter

A A
A A

Terbinafin – systemiskt Testmiljö

Terbinafin – systemiskt

Klass : A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Azurifin, Lamisil, Terbinafin 2care4, Terbinafin Arrow, Terbinafin Blu......

Azurifin, Lamisil, Terbinafin 2care4, Terbinafin Arrow, Terbinafin Bluefish, Terbinafin Ebb, Terbinafin Hexal, Terbinafin Medical Valley, Terbinafin Mylan, Terbinafin Orifarm, Terbinafin STADA, Terbinafin ratiopharm
ATC-koder

D01BA02

D01BA02
Substanser

terbinafin, terbinafinhydroklorid

terbinafin, terbinafinhydroklorid
Sammanfattning

Kvinnor och män har likvärdig effekt av terbinafin vid behandling av tånagelsvamp.

Kvinnor och män har likvärdig effekt av terbinafin vid behandling av tånagelsvamp.
Background

Most  published studies show a higher prevalence of onychomycosis in men. However, the male/female ratio varies between study population and study types. In population-based studies, the male/female ratio was 1.6. In hospital-based studies, the male/female ratio was 1.9 in North America, 1.5 in Europe, 0.8 in South America [1].

Pharmacokinetics and dosing
No studies with a sex analysis regarding the pharmacokinetics or dosing of terbinafine have been found.

Effects
No sex differences in patient-reported outcomes were shown after 12 weeks of treatment with oral terbinafine 250 mg/day in patients with toenail onychomycosis (309 men, 195 women) [2]. Also, another smaller study in patients with toenail onychomycosis treated with terbinafine 250 mg/day for 12 weeks (40 men, 34 women) showed no sex differences in mycological cure (defined as negative 20% KOH test and a negative mycological culture) [3].

Adverse effects
No studies with a sex analysis regarding adverse effects of terbinafine have been found.

Reproductive health issues
Regarding teratogenic aspects, please consult Jan......

Visa hela bakgrundstexten

Most  published studies show a higher prevalence of onychomycosis in men. However, the male/female ratio varies between study population and study types. In population-based studies, the male/female ratio was 1.6. In hospital-based studies, the male/female ratio was 1.9 in North America, 1.5 in Europe, 0.8 in South America [1]. # Pharmacokinetics and dosing No studies with a sex analysis regarding the pharmacokinetics or dosing of terbinafine have been found. # Effects No sex differences in patient-reported outcomes were shown after 12 weeks of treatment with oral terbinafine 250 mg/day in patients with toenail onychomycosis (309 men, 195 women) [2]. Also, another smaller study in patients with toenail onychomycosis treated with terbinafine 250 mg/day for 12 weeks (40 men, 34 women) showed no sex differences in mycological cure (defined as negative 20% KOH test and a negative mycological culture) [3]. # Adverse effects No studies with a sex analysis regarding adverse effects of terbinafine have been found. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler män än kvinnor hämtade ut tabletter innehållande terbinafin (ATC-kod D01BA02) på recept i Sverige år 2021, totalt 12 425 män och 7 380 kvinnor. Det motsvarar 2,4 respektive 1,4 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 45-54 år hos båda könen. I genomsnitt var tabletter innehållande terbinafin 1,7 gånger vanligare hos män [4].
Referenser

Visa referenser

  1. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014;28:1480-91.

  2. Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18(1):46-52.

  3. Cohen AD, Medvesovsky E, Shalev R, Biton A, Chetov T, Naimer S et al. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis. J Dermatolog Treat. 2003;14:237-42.

  4. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]

  1. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014;28:1480-91.
  2. Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18(1):46-52.
  3. Cohen AD, Medvesovsky E, Shalev R, Biton A, Chetov T, Naimer S et al. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis. J Dermatolog Treat. 2003;14:237-42.
  4. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]
Uppdaterat

Litteratursökningsdatum: 9/16/2022

Litteratursökningsdatum: 9/16/2022
Fasstexter

Visa fasstexter